Mediator affair takes up EMA resources, anti-fraud investigation could soak more
This article was originally published in SRA
The European Medicines Agency has had to allocate "considerable" unplanned resources to dealing with the Mediator drug affair, according to its half-year report1. The agency is likely to dedicate even more to dealing with the fallout as an anti-fraud investigation into the agency in connection with the scandal is underway. Meanwhile, other planned work, including implementing new pharmacovigilance legislation, has been delayed, according to the report.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.
European industry association wants global convergence on development requirements, though the European Medicines Agency says that this would prove challenging.